Cancer therapeutics: Targeting the dark side of Myc
- 1 November 2005
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 41 (16), 2485-2501
- https://doi.org/10.1016/j.ejca.2005.08.017
Abstract
No abstract availableKeywords
This publication has 186 references indexed in Scilit:
- c-Myc-regulated microRNAs modulate E2F1 expressionNature, 2005
- A microRNA polycistron as a potential human oncogeneNature, 2005
- Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formationCancer Cell, 2005
- N and C-terminal Sub-regions in the c-Myc Transactivation Region and their Joint Role in Creating Versatility in Folding and BindingJournal of Molecular Biology, 2005
- Targeted cancer therapyNature, 2004
- MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancerNature, 2004
- Analysis of genomic targets reveals complex functions of MYCNature Reviews Cancer, 2004
- RETRACTED: Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesisCancer Cell, 2003
- Myc suppression of the p21Cip1 Cdk inhibitor influences the outcome of the p53 response to DNA damageNature, 2002
- c-myc Suppression in Burkitt's Lymphoma CellsBiochemical and Biophysical Research Communications, 2002